All In Biotech

Drug Trial Radar · NCT06539481

Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.

A Non-randomised, Open-label, Uncontrolled, Multi-centre, Phase IIIb Study Evaluating the Safety and Efficacy of Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Paediatric Subjects From 6 Years to Less Than 18 Years With Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Last checked: Nov 20, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Aug 31, 2024

Primary completion

Jul 15, 2026

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Alimera SciencesIndustry
Sponsor type
Industry
First posted
Aug 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim is to test how safe and effective the medicine ILUVIEN® (190μg) is for children and adolescents, who have non-infectious uveitis that keeps coming back and affects the back of the eye. The main thing Alimera wants to find out is how well the implant works for treating non-infectious uveitis in the back of the eye. Treatment success will be measured after 6 months of using the implant. The treatment will be considered successful if two things happen: 1. No swelling in the back of the eye called cystoid macular oedema; 2. A decrease in the cloudiness inside the eye, called vitreous haze, by at least two levels compared to how it was before the treatment, or the vitreous haze is completely gone. Participants will: 1. Receive a single treatment with ILUVIEN®, which is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye for up to 36 months. 2. Be followed for 36 months for checkups and tests

Conditions

  • Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Interventions

  • fluocinolone acetonide 190 microgramsDrug

    ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze.Time frame: 6 months after administration
  2. Rate of cataract formation and Rate of IOP elevationTime frame: 6 months after administration

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin Institute of Health Department of Ophthalmology

    Berlin, Germany · Not yet recruiting

  • Augenzentrum am St. Franziskus-Hospital Münster

    Münster, Germany · Recruiting

  • Hospital Universitario Cruces

    Bilbao, Spain · Recruiting

  • Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • University of Bristol Bristol Medical School

    Bristol, United Kingdom · Recruiting

  • Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield Children NHS Foundation Trust

    Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.